Cellevate selected to enter negotiations with EIC Fund for potential follow-on equity investment to support the company’s next growth phase in vaccine manufacturing

February 18, 2026

LUND, Sweden – February 18, 2026 – Cellevate today announces that the company has been selected to enter negotiations with the European Innovation Council (EIC) Fund regarding a potential follow-on equity investment, to be syndicated with new investors in a financing round planned for the second half of 2026.

The financing will support Cellevate’s next growth phase in vaccine manufacturing, including production scale-up of the Cellevat3d® VAX nanofiber products, expanded evaluations with major vaccine manufacturers and strategic partners, industrial bioreactor integration in large scale, and international commercial expansion.

“We are proud to be one of 61 companies selected by the EIC following a highly competitive process. This recognition confirms the potential of our nanofiber technology to transform vaccine biomanufacturing by enabling >10x higher viral titers, faster scale-up, and significantly improved production efficiency and sustainability. We look forward to the negotiation and due diligence process for this potential follow-on investment from EIC Fund and we are grateful for their support since the beginning of our industrial journey in 2022,” says Laura Chirica, CEO of Cellevate.

Further information will be communicated at a later stage.

For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com

About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The company is ISO 9001:2015 certified and has implemented GMP processes for production in clean room. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.

For more information, please visit www.cellevate.com.

About EIC Fund
The European Innovation Council Fund from the European Commission is a deep tech investor across all technologies. The EIC Fund aims to fill a critical financing gap, to support companies in the development and commercialisation of disruptive technologies. With its large network of capital providers and strategic partners it shares risk and crowds in market players.

More information: https://eic.ec.europa.eu/eic-fund_en